This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia
by Zacks Equity Research
Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.
Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of 3.08% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 46.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 22.22% and 9.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 8.67% and 4.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Humanigen Inc. (HGEN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Humanigen Inc. (HGEN) delivered earnings and revenue surprises of -26.47% and 0.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -24.44% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
LAVA Therapeutics N.V. (LVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
LAVA Therapeutics N.V. (LVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Humanigen Inc. (HGEN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Humanigen Inc. (HGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Selecta Biosciences, Inc. (SELB) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 300% and 83.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal
by Zacks Equity Research
The NIAID's ACTIV-5/BET-B study evaluating Humanigen's (HGEN) lenzilumab plus remdesivir in hospitalized COVID-19 patients fails to meet the primary endpoint. Stock down.
KaloBios Pharmaceuticals Inc. (HGEN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
KaloBios Pharmaceuticals Inc. (HGEN) delivered earnings and revenue surprises of 34.69% and 0.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 7.14% and 5.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Humanigen (HGEN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.
Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -20.25% and 6.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
KaloBios Pharmaceuticals Inc. (HGEN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
KaloBios Pharmaceuticals Inc. (HGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Sell Stocks for September 14th
by Zacks Equity Research
ATR, FTAI, HGEN, LMB, and MRSN have been added to the Zacks Rank #5 (Strong Sell) List on September 14, 2021.
Implied Volatility Surging for Humanigen (HGEN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.
KaloBios Pharmaceuticals Inc. (HGEN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
KaloBios Pharmaceuticals Inc. (HGEN) delivered earnings and revenue surprises of -160.87% and -98.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Humanigen (HGEN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Humanigen (HGEN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.
Emergent (EBS) Beats on Q1 Earnings, Cuts Contract Revenue View
by Zacks Equity Research
Emergent's (EBS) earnings in the first quarter of 2021 beat estimates while revenues miss the same. It lowers guidance for revenues from CDMO services. Stock down.
Is the Options Market Predicting a Spike in Humanigen (HGEN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.
Do Options Traders Know Something About Humanigen (HGEN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.
Is a Surprise Coming for Humanigen (HGEN) This Earnings Season?
by Zacks Equity Research
Humanigen (HGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.